Emerging RAS-directed therapies for cancer

Abstract excerpt

RAS oncogenes are the most commonly mutated oncogenes in human cancer, and RAS-mutant cancers represent a major burden of human disease. Though these oncogenes were discovered decades ago, recent years have seen major advances in understanding of their structure and function, including the therapeutic and prognostic significance of diverse isoforms. Targeting of these mutations has proven difficult, despite some...

Topics

Join the communities discussing this publication.

• Monoclonal and Polyclonal Antibodies Research
• Protein Degradation and Inhibitors
• Ubiquitin and proteasome pathways